Module 1 (US) — Administrative & US Prescribing Information (OBX-319)
📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 1 (US) — Administrative & US Prescribing Information (OBX-319)
Why it exists. Region-specific administrative content the agency requires in front of the scientific dossier.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. —
Module 1 (US) — Administrative & US Prescribing Information (OBX-319)
Document ID: M1-US
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): 21 CFR 201.57 (PLR)
US Prescribing Information (Highlights) — OBX-319
1 INDICATIONS AND USAGE. OBX-319 is indicated for the treatment of Systemic Lupus Erythematosus (moderate-to-severe active).
2 DOSAGE AND ADMINISTRATION. Administer by subcutaneous injection at the dose evaluated in the clinical programme; see Clinical Studies (14).
4 CONTRAINDICATIONS. Known serious hypersensitivity to the product or its excipients; active serious infection, including active tuberculosis.
6 ADVERSE REACTIONS.
| Arm | N | ≥1 TEAE | SAE | Deaths | Discontinued |
|---|---|---|---|---|---|
| OBX-319 High | 162 | 78 | 2 | 1 | 17 |
| OBX-319 Low | 158 | 74 | 1 | 0 | 13 |
| Placebo | 160 | 78 | 1 | 0 | 10 |
Most frequent adverse events (subjects, by arm)
| Preferred term | OBX-319 High | OBX-319 Low | Placebo |
|---|---|---|---|
| Upper respiratory tract infection | 25 | 18 | 13 |
| Urinary tract infection | 16 | 14 | 14 |
| Nasopharyngitis | 11 | 14 | 16 |
| Headache | 11 | 11 | 16 |
| Lupus nephritis flare | 4 | 8 | 16 |
| Injection site reaction | 14 | 7 | 6 |
14 CLINICAL STUDIES. In OBX319-301, a randomized, double-blind, placebo-controlled study, the following efficacy was observed for SRI-4 response at Week 52 (operationalised as low disease activity, SLEDAI-2K <= 4):
| Arm | N | LS-mean Δ SLEDAI-2K @ Wk 52 (points) | Diff vs placebo (95% CI) | p |
|---|---|---|---|---|
| OBX-319 High | 162 | -6.37 | -2.91 (-3.12, -2.69) | 0.0000 |
| OBX-319 Low | 158 | -5.62 | -2.17 (-2.38, -1.95) | 0.0000 |
| Placebo | 160 | -3.46 | — (reference) | — |
Responder analysis — Low disease activity (SLEDAI-2K <= 4)
| Arm | N | Responders, n/N | Rate | Risk diff vs placebo (95% CI, %) | p |
|---|---|---|---|---|---|
| OBX-319 High | 145 | 76/145 | 52.4% | 46.4% (37.4, 55.4) | 0.0000 |
| OBX-319 Low | 145 | 49/145 | 33.8% | 27.8% (19.2, 36.4) | 0.0000 |
| Placebo | 150 | 9/150 | 6.0% | — (reference) | — |
Region-specific administrative content and the USPI are written to 21 CFR 201.57 (PLR); clinical figures trace to the Module 5 study report.
Comments (0)
No comments yet. Be the first to say something!